In in vitro and in vivo models of DLBCL (cell lines: Toledo, WSU-DLC2, SU-DHL-4, SU-DHL-6), MCL and FL potent daratumumab-mediated ADCC and ADCP was demonstrated independently of CD38 expression [83]. This evidence concerns the gene CD38 and diffuse large B-cell lymphoma.